natgillin/translations-raw huggingface dataset:
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 600/100 mg twice daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum 
Farmakokinetički rezultati ukupnog darunavira nakon primjene darunavira/ritonavira 600/100 mg dvaput na dan, kao dijela antiretrovirusnog režima liječenja tijekom drugog trimestra trudnoće, trećeg trimestra trudnoće i postpartalnog razdoblja
If efavirenz is to be used in combination with darunavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used (see section 4.5). 
Ako je potrebno primjenjivati efavirenz u kombinaciji s darunavirom, za darunavir/ritonavir se mora primijeniti režim od 600/100 mg dvaput na dan (vidjeti dio 4.5).
The combination of rifapentine and darunavir with concomitant low dose ritonavir is not recommended. 
Kombinacija rifapentina i darunavira s istodobno primijenjenom niskom dozom ritonavira se ne preporučuje.
Co-administration of darunavir and ritonavir with medicinal products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone) may result in decreased systemic exposure to such medicinal products, which could decrease or shorten their therapeutic effect. 
Istodobna primjena darunavira i ritonavira s lijekovima koji se primarno metaboliziraju putem CYP2C9 (poput varfarina) te CYP2C19 (poput metadona), može rezultirati smanjenjem sistemske izloženosti tim lijekovima, što može smanjiti ili skratiti njihov terapijski učinak.
At 48 weeks, virologic response, defined as the percentage of patients with plasma HIV-1 RNA level < 50 copies/ml, with darunavir/ritonavir 800/100 mg once daily treatment was demonstrated to be non-inferior (at the pre-defined 12% non-inferiority margin) compared to darunavir/ritonavir 600/100 mg twice daily for both ITT and OP populations. 
Nakon 48 tjedana, pokazalo se da virološki odgovor, definiran kao postotak bolesnika s razinom u plazmi HIV-1 RNK < 50 kopija/ml, nije inferioran uz liječenje darunavirom/ritonavirom od 800/100 mg jedanput na dan (pri prethodno definiranoj granici neinferiornosti od 12%) u usporedbi s darunavirom/ritonavirom od 600/100 mg dvaput na dan u ITT i OP populacijama.
If you forget to take Darunavir Krka If you notice within 6 hours, you must take your missed dose immediately. 
Ako ste zaboravili uzeti lijek Darunavir Krka Ako primijetite da niste uzeli lijek unutar 6 sati, tablete morate uzeti odmah, uvijek s ritonavirom i hranom.
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with boosted darunavir is not recommended. 
Ne preporučuje se istodobna primjena tadalafila za liječenje plućne arterijske hipertenzije i pojačanog darunavira.
Third Trimester of pregnancy (n=15) 
Treće tromjesečje trudnoće (n=15)
21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents. 
- 21 pedijatrijski bolesnik u dobi od 3 do < 6godina i težine od 10kg do <20kg (16 ispitanika imalo je od 15 kg do < 20 kg), prethodno liječeni ART-om, a inficirani su virusom HIV-1 te su primali darunavir oralnu suspenziju s niskom dozom ritonavira dvaput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
Co-administration of tadalafil for the treatment of pulmonary arterial hypertension with darunavir and low dose ritonavir is not recommended. 
Ne preporučuje se istodobna primjena tadalafila za liječenje plućne arterijske hipertenzije i darunavira s niskom dozom ritonavira.
In contrast to these data with darunavir /ritonavir, darunavir/cobicistat may increase these antidepressant plasma concentrations (CYP2D6 and/or CYP3A inhibition). 
Dezipramin Imipramin Nortriptilin Trazodon podatke s darunavirom/ritonavirom, darunavir/kobicistat može povisiti koncentracije tih antidepresiva u plazmi (CYP2D6 i/ili CYP3A inhibicija).
Darunavir Krka is available in bottles containing 30 film-coated tablets (1 bottle of 30 film-coated tablets), 60 film-coated tablets (2 bottles of 30 film-coated tablets), 90 film-coated tablets (3 bottles of 30 film-coated tablets) and 180 film-coated tablets (6 bottles of 30 film-coated tablets) in a boxes. 
Darunavir Krka dostupne su u bočicama koje sadrže 30 filmom obloženih tableta (1 bočica s 30 filmom obloženih tableta), 60 filmom obloženih tableta (2 bočice s 30 filmom obloženih tableta), 90 filmom obloženih tableta (3 bočice s 30 filmom obloženih tableta) i 180 filmom obloženih tableta (6 bočica s 30 filmom obloženih tableta) u kutiji.
Darunavir with low dose ritonavir with triazolam or oral midazolam is contraindicated (see section 4.3) 
Darunavir s niskom dozom ritonavira je kontraindicirana s triazolamom ili oralnim midazolamom (vidjeti dio 4.3).
Your doctor should do blood tests before you start Darunavir Krka. 
Prije započinjanja lijeka Darunavir Krka liječnik Vam treba napraviti krvne pretrage.
Therefore, co-administration of darunavir with low dose ritonavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). 
Stoga je istodobna primjena darunavira s niskom dozom ritonavira i sildenafila kada se primjenjuje za liječenje plućne arterijske hipertenzije kontraindicirana (vidjeti dio 4.3).
The recommended dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with darunavir with low dose ritonavir. 
Preporučena doza emtricitabin/tenofoviralafenamida kada se uzima s darunavirom s niskom dozom ritonavira je 200/10 mg jedanput na dan.
The combination of avanafil and boosted darunavir is contraindicated (see section 4.3). 
Kombinacija avanafila i pojačanog darunavira je kontraindicirana (vidjeti dio 4.3).
Respiratory, thoracic and mediastinal disorders uncommon dyspnoea, cough, epistaxis, throat irritation rare rhinorrhoea 
Poremećaji dišnog sustava, prsišta i sredoprsja manje često dispneja, kašalj, epistaksa, nadraženost grla rijetko rinoreja
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with darunavir and low dose ritonavir has not been established. 
Nije ustanovljena sigurna i učinkovita doza sildenafila za liječenje pulmonalne arterijske hipertenzije s istodobnom primjenom darunavira primijenjenog istodobno s niskom dozom ritonavira.
Exposure to these immunosuppressants will be increased when co-administered with boosted darunavir. 
Izloženost tim imunosupresivima bit će povećana ako se primjenjuju istodobno s pojačanim darunavirom. (CYP3A inhibicija)
Darunavir must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products (see section 5.2). 
Darunavir se uvijek mora primjenjivati peroralno s niskom dozom ritonavira koji pospješuje farmakokinetiku i u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 5.2).
If efavirenz is to be used in combination with darunavir /ritonavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used (see section 4.4). 
Ako se efavirenz primjenjuje u kombinaciji s darunavirom/ritonavirom, mora se primijeniti darunavir/ritonavir 600/100 mg u režimu doziranja dvaput na dan (vidjeti dio 4.4).
Darunavir must always be given orally with cobicistat or low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products (see section 5.2). 
Darunavir se uvijek mora primjenjivati peroralno s kobicistatom ili niskom dozom ritonavira kao farmakokinetičkim pojačivačem, te u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 5.2).
#, a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with darunavir and low dose ritonavir. 
Sildenafil Tadalafil Vardenafil sistemska izloženost sildenafilu unosom jednokratne doze od 100 mg samo sildenafila i unosa jednokratne doze od 25 mg sildenafila istodobno primijenjenog s darunavirom i niskom dozom ritonavira.
The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer. 
Interakcijski profil darunavira ovisi o tome je li kao farmakokinetički pojačivač korišten ritonavir ili kobicistat.
Darunavir boosted with cobicistat is more sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and strong CYP3A inducers is therefore contraindicated (see section 4.3),and concomitant use with weak to moderate CYP3A inducers is not recommended (see section 4.5). 
Farmakokinetički pojačivači i istodobno primijenjeni lijekovi Profil interakcija darunavira različit je i ovisan o tome je li pojačan s ritonavirom ili s kobicistatom: - Darunavir pojačan s kobicistatom osjetljiviji je na CYP3A indukciju: stoga je kontraindicirana istodobna primjena darunavira/kobicistata i snažnih induktora CYP3A (vidjeti dio 4.3), te se ne preporučuje istodobna primjena sa slabim do umjerenim induktorima CYP3A (vidjeti dio 4.5).
Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0. 
Pripisane vrijednosti izračunate prema TLOVR algoritmu Bolesnik koji nije završio ispitivanje zabilježen je kao neuspjeh: bolesnicima koji su prijevremeno prekinuli ispitivanje pripisana je promjena jednaka 0.
Concomitant use of sildenafil or tadalafil for the treatment of pulmonary arterial hypertension and darunavir coadministered with low dose ritonavir may increase plasma concentrations of sildenafil or tadalafil. 
Istodobna primjena sildenafila ili tadalafila za liječenje plućne arterijske hipertenzije i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati koncentracije sildenafila ili tadalafila u plazmi. (CYP3A inhibicija)
6/l (see section 
6/l (vidjeti dijelove
Cobicistat and ritonavir inhibit CYP3A, thereby increasing the plasma concentrations of darunavir considerably. 
Kobicistat i ritonavir inhibiraju CYP3A te na taj način značajno povećavaju koncentracije darunavira u plazmi.
Once daily dosing Weight 
Doziranje jedanput na dan
Concomitant use of bosentan and boosted darunavir may increase plasma concentrations of bosentan. 
Istodobna primjena bosentana i pojačanog darunavira može povećati koncentracije bosentana u plazmi.
Patients with no/nonnaïve use of ENF Patients with naïve use of ENF 
Bolesnici koji prije nisu liječeni s ENF
Concomitant use of sildenafil or tadalafil for the treatment of pulmonary arterial hypertension and boosted darunavir may increase plasma concentrations of sildenafil or tadalafil. 
Istodobna primjena sildenafila ili tadalafila za liječenje plućne arterijske hipertenzije i pojačanog darunavira može povećati koncentracije sildenafila ili tadalafila u plazmi. (CYP3A inhibicija)
The use of these medicines with darunavir/cobicistat is contraindicated (see section 4.3). 
Primjena ovih lijekova s darunavirom/kobicistatom je kontraindicirana (vidjeti dio 4.3).
Boosted darunavir and rilpivirine can be used without dose adjustments. 
Pojačan darunavir i rilpivirin mogu se primijeniti bez prilagodbe doze.
In women receiving darunavir/cobicistat during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 49%, 56% and 92% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 37%, 50% and 89% lower, respectively, as compared with postpartum. 
U žena koje uzimaju darunavir/kobicistat tijekom drugog tromjesečja trudnoće, srednje intra-individualne vrijednosti Cmax, AUC24h i Cmin za ukupni darunavir bile su 49%, 56% odnosno 92% niže u usporedbi s postpartalnim razdobljem; tijekom trećeg tromjesečja trudnoće, vrijednosti Cmax, AUC24h i Cminza ukupni darunavir bile su 37%, 50% i 89% niže u usporedbi s postpartalnim razdobljem.
It is not recommended to coadminister boosted darunavir and boceprevir. 
Ne preporučuje se istodobna primjena pojačanog darunavira i boceprevira.
Concominant use of everolimus or irinotecan and darunavir coadministered with low dose ritonavir is not recommended. 
Istodobno uzimanje everolimusa ili irinotekana i darunavira s niskom dozom ritonavira se ne preporučuje.
Based on theoretical considerations darunavir co-administered with cobicistat is expected to increase metformin plasma concentrations. 
Temeljem teorijskih postavki očekuje se da će darunavir istodobno primijenjen s kobicistatom povećati koncentracije metformina u plazmi.
Postpartum (6-12 weeks) (n=6) 
Postpartalno razdoblje (6-12 tjedana) (n=6)
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 800/100 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum 
Farmakokinetički rezultati ukupnog darunavira nakon primjene darunavira/ritonavira 800/100 mg jedanput dnevno kao dijela antiretrovirusnog režima liječenja tijekom drugog trimestra trudnoće, trećeg trimestra trudnoće i postpartalnog razdoblja
Postpartum (6-12 weeks) (n=12) 
Postpartalno razdoblje (6-12 tjedana) (n=12)
ethinylestradiol AUC ↓ 44% ethinylestradiol Cmin ↓ 62% ethinylestradiol Cmax ↓ 32% norethindrone AUC ↓ 14% norethindrone Cmin ↓ 30% norethindrone Cmax ↔ with darunavir/ritonavir 
etinilestradiol AUC ↓ 44% etinilestradiol Cmin ↓ 62% etinilestradiol Cmax ↓ 32% noretindron AUC ↓ 14% noretindron Cmin ↓ 30% noretindron Cmax ↔ s darunavirom/ritonavirom
With baseline HIV-RNA ≥ 
S početnom HIV-RNK
800 milligram Darunavir Krka (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) together with 100 milligram ritonavir once daily. 
800 miligrama lijeka Darunavir Krka (2 tablete koje sadrže 400 miligrama lijeka Darunavir Krka ili 1 tableta koja sadrži 800 miligrama lijeka Darunavir Krka) zajedno sa 100 miligrama ritonavira jedanput na dan.
Boosted darunavir can be used with these NRTIs without dose adjustment. 
Pojačan darunavir može se primijeniti s ovim NRTI lijekovima bez prilagodbe doze.
Therefore, therapy with darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with darunavir/cobicistat should be switched to an alternative regimen (see sections 4.2 and 4.6). 
Stoga se liječenje darunavirom/kobicistatom ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja darunavirom/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.2 i 4.6).
darunavir/ ritonavir darunavir/ ritonavir 800/100 mg darunavir/ ritonavir darunavir/ ritonavir 600/100 mg 
darunavir/ ritonavir 800/100 mg lopinavir/ ritonavir 800/200 mg
Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1). 
Smjernice za primjenu darunavira moraju se temeljiti na genotipskim i fenotipskim pretragama (kada su dostupne) kao i dosadašnjem liječenju (vidjeti dijelove 4.2, 4.4 i 5.1).
Darunavir co-administered with low dose ritonavir can be co-administered with proton pump inhibitors without dose adjustments. 
Darunavir primijenjen istodobno s niskom dozom ritonavira može biti primijenjen istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
Therefore, therapy with darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with darunavir/cobicistat should be switched to an alternative regimen (see sections 4.4 and 4.6). 
Stoga se liječenje darunavirom/kobicistatom ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja darunavirom/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.4 i 4.6).
Darunavir co-administered with low dose ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk. 
Darunavir primijenjen istodobno s niskom dozom ritonavira se smije primjenjivati tijekom trudnoće samo ako potencijalna korist opravdava potencijalni rizik.
Etravirine 100 mg twice daily etravirine AUC ↓ 37% etravirine Cmin ↓ 49% etravirine Cmax ↓ 32% darunavir AUC ↑ 15% darunavir Cmin ↔ darunavir Cmax ↔ 
Etravirin 100 mg dvaput na dan etravirin AUC ↓ 37% etravirin Cmin ↓ 49% etravirin Cmax ↓ 32% darunavir AUC ↑ 15% darunavir Cmin ↔ darunavir Cmax ↔
The combination product lopinavir/ritonavir (see section 4.5). 
Istodobna primjena s kombinacijom lijekova lopinavir/ritonavir (vidjeti dio 4.5).
Dexamethasone may decrease plasma concentrations of darunavir. 
Deksametazon može smanjiti koncentracije darunavira u plazmi. (indukcija CYP3A)
Lopinavir/ritonavir 400/100 mg twice daily + OBR N=297 
Lopinavir/ritonavir 400/100 mg dvaput na dan + OOR N=297
In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10 
U bolesnika prethodno liječenih ART-om DRV-RAM*, a imaju plazmatsku HIV1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
Therapy with darunavir/cobicistat should not be initiated during pregnancy, and women who become pregnant during therapy with darunavir/cobicistat should be switched to an alternative regimen (see sections 4.2 and 4.4). 
Liječenje darunavirom/kobicistatom se ne smije započinjati tijekom trudnoće, a žene koje zatrudne tijekom liječenja darunavirom/kobicistatom trebaju prijeći na zamjenski režim (vidjeti dijelove 4.2 i 4.4).
Boosted darunavir may increase antifungal plasma concentrations and posaconazole, isavuconazole, itraconazole or fluconazole may increase darunavir concentrations. 
Pojačan darunavir može povećati koncentracije antifungika u plazmi , a posakonazol, izavukonazol, itrakonazol ili flukonazol mogu povećati koncentracije darunavira. (CYP3A inhibicija i/ili P-gp inhibicija)
Recommended dose for treatment-experienced paediatric patients (3 to 17 years) with darunavir and ritonavir 
Preporučena doza darunavira i ritonavira a za pedijatrijske bolesnike (od 3 do 17 godina) koji su prethodno liječeni
Carbamazepine 200 mg twice daily carbamazepine AUC ↑ 45% carbamazepine Cmin ↑ 54% carbamazepine Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15% darunavir Cmax ↔ 
Karbamazepin 200 mg dvaput na dan karbamazepin AUC ↑ 45% karbamazepin Cmin ↑ 54% karbamazepin Cmax ↑ 43% darunavir AUC ↔ darunavir Cmin ↓ 15% darunavir Cmax ↔
You must eat a meal or a snack within 30 minutes prior to taking your Darunavir Krka and ritonavir. 
Unutar 30 minuta prije uzimanja lijeka Darunavir Krka i ritonavira morate pojesti obrok ili nešto prigristi.
ANTIFUNGALS Voriconazole 
ANTIMIKOTICI Vorikonazol
If you notice after 12 hours, then skip the intake and take the next doses as usual. 
Ako primijetite da ste propustili uzeti lijek nakon 12 sati, preskočite propuštenu dozu i uzmite iduću dozu u sljedećem redovnom terminu za uzimanje lijeka.
Do not stop taking Darunavir Krkawithout talking to your doctor first Anti-HIVmedicinesmaymake you feel better. 
Nemojte prestati uzimati lijek Darunavir Krka bez prethodnog razgovora s liječnikom
If you notice after 6 hours, then skip the intake and take the next doses as usual. 
Ako primijetite da ste propustili uzeti lijek nakon 6 sati, preskočite propuštenu dozu i uzmite iduću dozu u sljedećem redovnom terminu za uzimanje lijeka.
The combination of rifampicin and darunavir with concomitant low dose ritonavir is contraindicated (see section 4.3). 
Kombinacija rifampicina i darunavira primijenjenog istodobno s niskom dozom ritonavira je kontraindicirana (vidjeti dio 4.3).
based on published data with darunavir/ritonavir 
darunavir/ritonavi
Concomitant use of bosentan and darunavir co-administered with low dose ritonavir may increase plasma concentrations of bosentan. 
Istodobna primjena bosentana i darunavira primijenjenog s niskom dozom ritonavira može povećati koncentracije bosentana u plazmi.
Based on theoretical considerations boosted darunavir is expected to increase the exposure of lomitapide when coadministered. 
Temeljeno na teorijskim postavkama, očekuje se da će pojačani darunavir povećati izloženost lomitapidu kada se primjenjuju istodobno. (CYP3A inhibicija)
450 mg darunavir /60 mg ritonavir twice daily 
450 mg darunavir /60 mg ritonavir dvaput na dan
Concomitant use of everolimus and boosted darunavir is not recommended. 
Istodobna primjena everolimusa i pojačanog darunavira se ne preporučuje.
The interaction profile of darunavir depends on whether ritonavir is used as pharmacokinetic enhancer. 
Profil interakcija darunavira ovisan je o tome je li kao farmakokinetički pojačivač primijenjen ritonavir.
Reproductive system and breast disorders uncommon gynaecomastia* 
Poremećaji reproduktivnog sustava i dojki manje često ginekomastija*
Take Darunavir Krka always together with ritonavir. 
- Lijek Darunavir Krka uvijek uzimajte zajedno s ritonavirom.
Combinations with optimised background regimen (OBRs) other than ≥ 2 NRTIs have not been studied in this population. 
U toj populaciji nisu ispitivane druge kombinacije s optimiziranim osnovnim režimom (OOR) osim s ≥ 2 NRTI (nukleozidni/nukleotidni inhibitori reverzne transkriptaze, od engl.
#, a comparable systemic exposure to sildenafil was observed for a single intake of 100 mg sildenafil alone and a single intake of 25 mg sildenafil co-administered with 
U ispitivanju interakcija primijećena je usporediva sistemska izloženost sildenafilu unosom jednokratne doze od 100 mg samo sildenafila i unosa jednokratne doze od 25 mg sildenafila istodobno primijenjenog s darunavirom i
Darunavir Krka 400 milligram and 800 milligram tablets are only to be used to construct the once daily 800 milligram regimen. 
Tablete Darunavir Krka od 400 miligrama i 800 miligrama primjenjuju se samo za dostizanje režima doziranja od 800 miligrama jedanput na dan.
Appropriate laboratory testing should be conducted prior to initiating therapy with darunavir used in combination with cobicistat or low dose ritonavir and patients should be monitored during treatment. 
Prije početka terapije darunavirom koji se uzima u kombinaciji s kobicistatom ili niskom dozom ritonavira, moraju se provesti odgovarajuća laboratorijska ispitivanja, te se bolesnike mora pratiti tijekom liječenja.
Second trimester of pregnancy (n=7) 
Drugo tromjesečje trudnoće (n=7)
Concomitant use of boosted darunavir with lovastatin and simvastatin is therefore contraindicated (see section 4.3). 
Istodobna primjena pojačanog darunavira s lovastatinom i simvastatinom je zbog toga kontraindicirana (vidjeti dio 4.3).
Dose for children 3 years of age and above, weighing more than 40 kilograms who have taken antiretroviral medicines before (your child's doctor will determine this) The dose is either: 
Doza za djecu u dobi od 3 godine i više, težine najmanje 40 kilograma koja su prethodno uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta)
In women receiving darunavir/ritonavir 800/100 mg once daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC24h and Cmin were 33%, 31% and 30% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC24h and Cmin values were 29%, 32% and 50% lower, respectively, as compared with postpartum. 
U žena koje su primale darunavir/ritonavir 800/100 mg jedanput dnevno tijekom drugog tromjesečja trudnoće, srednje intra-individualne vrijednosti za ukupni darunavir Cmax, AUC24h i Cmin bile su 33%, 31% odnosno 30% niže, uspoređujući s postpartalnim razdobljem; tijekom trećeg tromjesečja trudnoće, ukupne vrijednosti za darunavir Cmax, AUC24h i Cmin bile su 29%, 32% odnosno 50% niže, uspoređujući s postpartalnim razdobljem.
Second trimester of pregnancy (n=17) 
Drugo tromjesečje trudnoće (n=17)